Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.54 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.50 |
| ▸ | NPY2R | P49146 | 3/20 | 0.50 |
| ▸ | NPY4R | P50391 | 3/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339696 | 1.00 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL30302874 | 1.00 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL29800092 | 1.00 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL30305295 | 1.00 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL31110538 | 1.00 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL29732610 | 1.00 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL30093131 | 0.98 | MAGI3 (0.52) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL30945346 | 0.98 | MAGI3 (0.52) | KISS1RMAGI3IL23RNPY1RNPY2R | |
| SCHEMBL29732783 | 0.97 | MAGI3 (0.54) | KISS1RMAGI3IL23RPRMT1 | |
| SCHEMBL30305302 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | claimed |
| EP-4401754-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Peptilogics, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | claimed |
| WO-2023044339-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. (US) | 2023-03-23 | — | — | WO | claimed |
| US-20220332777-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-10-20 | — | — | US | claimed |
| US-20250320266-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12371463-B2 | Methods and compositions for treatment of antibiotic-resistant bacterial infections | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20220332777-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | KISS1R 3225/4885MAGI3 4082/4885IL23R 1571/4885 |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | KISS1R 3536/4885MAGI3 3116/4885IL23R 2492/4885 |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | KISS1R 3536/4885MAGI3 3116/4885IL23R 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.